Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595Phase 2Recruiting
- Sponsor
- Adagene
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of muzastotug in solid tumor and colorectal cancer (CRC) (4 arms), sponsored by Adagene. Primary endpoints: Maximum Tolerated Dose at 6 months, Recommended Phase 2 Dose at 6 months and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
muzastotug
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05405595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405595.